Health Care, Pharmaceuticals, Biotech
May 21, 2026
California Supreme Court hears Gilead Tenofovir Cases, weighs scope of 'duty to innovate'
The California Supreme Court heard arguments in the Gilead Tenofovir litigation as justices examined whether drugmakers can be held liable for delaying safer alternatives under a broader "duty to innovate."
Tommy Huynh
Counsel
Arnold & Porter Kaye Scholer LLP
Email: tommy.huynh@arnoldporter.com
UCLA SOL; Los Angeles CA
Shutterstock
On May 6, 2026, the California Supreme Court heard oral argument in Gilead Tenofovir Cases, a product liability case that grapples with a novel theory of negligence liability based on a "duty to innovate." At issue is whether ...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In